Skip to main content

Advertisement

SpringerLink
Log in

Oxalate crystal deposition disease

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

In addition to monosodium urate, calcium pyrophosphate dihydrate, and apatite crystals, oxalate crystals are less often found in synovial fluids in association with acute or chronic arthritis. Oxalate crystal deposition disease is seen in patients with primary hyperoxaluria types 1 and 2 (PH1 and 2) and in patients with end-stage renal disease managed with long-term dialysis. Oxalate crystal deposits are found mainly in kidneys, bone, skin, and vessels, and less often inside the joints. Musculoskeletal and systemic manifestations of oxalate crystal deposition disease may be confused with those observed with the other most common types of crystal deposition diseases. Clinical and radiographic features include calcium oxalate osteopathy, acute and chronic arthropathy with chondrocalcinosis, synovial calcification, and miliary skin calcium oxalate deposits and vascular calcifications that affect mainly the hands and feet. Systemic lifethreatening cardiovascular, neurologic, and hematologic manifestations are rare. Genomic DNA studies have identified those genetic defects of PH1 and PH2 that allow a precise early diagnosis. Kidney transplantation has poor outcome as a result of graft oxalosis. Combined liver and kidney transplantation is the treatment of choice in patients with PH1 and advanced renal failure. Pre-emptive isolated liver transplantation is the preferred treatment in patients who develop the disease during infancy with progressive manifestations of oxalosis. These novel findings in the understanding of the molecular and enzymatic aspects of primary hyperoxalurias have provided a more rational basis for the management and prevention of oxalate crystal deposition disease. This information may lead to a better understanding and effective management of other common calcium-containing crystal deposition diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reginato AJ, Falasca GF, Usmani Q: Do we really need to pay attention to the less common crystals? Review about the clinical significance of rare crystals found in synovial fluid in articular tissues. Curr Opin Rheumatol 1999, 11:446–452.

    Article  PubMed  CAS  Google Scholar 

  2. Reginato AJ: Calcium oxalate and other crystals or particles associated with arthritis. In Arthritis and Allied Conditions, edn 14. Edited by Koopman WJ. Baltimore: Williams & Wilkins; 2000:2393–2414. A review of the clinical, pathologic, and crystallographic features of uncommon crystals associated with arthritis, including primary and secondary oxalosis.

    Google Scholar 

  3. Watts RW: The clinical spectrum of the primary hyperoxalurias and their treatment. J Nephrol 1998, 11:4–7. An excellent review of the clinical spectrum of primary hyperoxalurias and management.

    PubMed  Google Scholar 

  4. Schumacher HR: Introduction to the crystalline arthropathies. In Gout, Hyperuricemia and Other Crystal Associated Arthropathies. Edited by Smith C, Holers M. New York: Marcel Dekker; 1998:227.

    Google Scholar 

  5. Danpure CJ: Molecular and cell biology of primary hyperoxaluria type 1. Clin Invest 1994, 72:725–727.

    Article  CAS  Google Scholar 

  6. Watts RWE: Primary hyperoxaluria type 1. Q J Med 1994, 87:593–600.

    CAS  Google Scholar 

  7. Danpure CJ, Jennings PR, Fryer P, et al.: Primary hyperoxaluria type 1: genotypic and phenotypic heterogeneity. J Inherit Metab Dis 1994, 17:487–499.

    Article  PubMed  CAS  Google Scholar 

  8. Danpure CJ: The molecular basis of alanine: glyoxylate aminotransferase mistargeting: the most common cause of primary hyperoxaluria type 1. J Nephrol 1998, 11:8–12. This paper describes the molecular basis of alanine glyoxylate aminotransferase mistargeting from the peroxisomes to the mitochondria as a result of a common Pro II-Leu polymorphism.

    PubMed  Google Scholar 

  9. Leumann E, Hoppe B: The primary hyperoxalurias. J Am Soc Nephrol 2001, 12:1986–1993.

    PubMed  CAS  Google Scholar 

  10. Rumsby G: Biochemical and genetic diagnosis of the primary hyperoxalurias: a review. Mol Urol 2000, 4:349–354. In this study, mutation analysis was performed for the diagnosis of primary hyperoxaluria type 1 (PH1). DNA samples from 127 patients with high suspicion of primary hyperoxaluria were analyzed for the presence of G630A and T853C mutations. This study showed how genetic methods (mutation and linkage analysis) for diagnosing PH1 (and eventually PH2) may be useful.

    PubMed  CAS  Google Scholar 

  11. Milliner DS, Wilson DM, Smith LH: Phenotypic expression of primary hyperoxaluria: comparative features of types 1 and 2. Kidney Int 2001, 59:31–36. This report showed that the severity of disease expression is greater in primary hyperoxaluria (PH) type 1 than PH2. The difference may be caused by greater oxalate excretion and lower concentration of urine citrate and magnesium in patients with PH1 compared with PH2.

    Article  PubMed  CAS  Google Scholar 

  12. Pirulli D, Boniotto M, Puzzer D, et al.: Flexibility of melting temperature assay for rapid detection of insertions, deletions, single point mutations of the AXGT gene responsible for type 1 primary hyperoxalurias. Clin Chem 2000, 46:1842–1844.

    PubMed  CAS  Google Scholar 

  13. Milliner DS, Wilson DM, Smith LH: Clinical expression and long-term outcomes of primary hyperoxaluria types 1 and 2. J Nephrol 1998, 11:56–59.

    PubMed  Google Scholar 

  14. Lumb MJ, Danpure CJ: Functional synergism between the most common polymorphism in human alanine: glyoxylate aminotransferase and four of the most common disease causing-mutations. J Biol Chem 2000, 275:36415–36422.

    Article  PubMed  CAS  Google Scholar 

  15. Cochat P: Primary hyperoxaluria type 1. Kidney Int 1999, 55:2533–2547.

    Article  PubMed  CAS  Google Scholar 

  16. Maldonado I, Reginato AM, Reginato AJ: Familial calcium crystal diseases: what have we learned? Curr Opin Rheumatol 2001, 13:225–233. An update of genomic DNA studies in human and in mice of familial calcium pyrophosphate dihydrate deposition and apatite deposition diseases and other less common soft tissue calcification syndromes.

    Article  PubMed  CAS  Google Scholar 

  17. Hoffman GS, Schumacher HR, Paul H, et al.: Calcium oxalate microcrystalline-associated arthritis in the end stage renal disease. Ann Intern Med 1982, 97:36–42.

    PubMed  CAS  Google Scholar 

  18. Reginato AJ, Seoane JLF, Alvarez CB, et al.: Arthropathy and cutaneous calcinosis in hemodialysis oxalosis. Arthritis Rheum 1986, 29:1387–1396.

    Article  PubMed  CAS  Google Scholar 

  19. Abuelo G, Swartz ST, Reginato AJ: Cutaneous calcinosis after long term hemodialysis. Arch Int 1992, 152:1517–1520.

    Article  CAS  Google Scholar 

  20. Arbus GS, Sniderman S: Oxalosis with peripheral gangrene. Arch Pathol 1974, 97:107–110.

    PubMed  CAS  Google Scholar 

  21. Greer KE, Cooper PH, Campbell F, Westervelt FB: Primary oxalosis with livedo reticularis. Arch Dermatol 1980, 116:213–214.

    Article  PubMed  CAS  Google Scholar 

  22. Galimberti RL, Parra IH, Imperiali N, et al.: Fatal cutaneous necrosis in hemodialyzed patient with oxalosis. Int J Dermatol 1999, 38:918–920.

    Article  PubMed  CAS  Google Scholar 

  23. Lammie GA, Wardlaw J, Dennis M: Thrombo-embolic stroke, moya-moya phenomenon and primary oxalosis. Cerebrovasc Dis 1998, 8:45–50.

    Article  PubMed  CAS  Google Scholar 

  24. Johnson JS, Short AK, Hutchison A, et al.: Small intestinal infarction: a fatal complication of systemic oxalosis. J Clin Pathol 2000, 53:720–721.

    Article  PubMed  CAS  Google Scholar 

  25. O’Reilly MA, Meadows KP, Egan CA: Off center fold: narcotizing livedo reticularis. Diagnosis: primary hyperoxaluria. Arch Dermatol 2001, 37:957–962.

    Google Scholar 

  26. Singh S, Tai C, Ganz G, et al.: Steroid responsive pleuropericarditis and livedo reticularis in an unusual case of adultonset primary hyperoxaluria. Am J Kidney Dis 1999, 4:33–35. Pleuropericarditis and livedo reticularis are atypical adult presentations of primary hyperoxaluria that show dramatic clinical response to empiric steroid therapy. This suggests a role for the use of steroids in the management of the acute inflammatory symptoms of oxalosis.

    Google Scholar 

  27. Lomberts RVD, Proesmans W, Alexandre G, et al.: Reversible arterial spasm in an adolescent with primary oxalosis. Clin Nephrol 1998, 30:235–238.

    Google Scholar 

  28. Plorer A, Zelger B: Acute livedo racemosa in a patient with type 1 primary hyperoxaluria. Arch Dermatol 1996, 132:349.

    Article  PubMed  CAS  Google Scholar 

  29. Palka P, Duhig E, Carey L, Galbraith A: Primary oxalosis with cardiac involvement: echocardiographic features of acute form of cardiomyopathy. Circulation 2001, 103:122–123.

    Google Scholar 

  30. Lewis RD, Lowenstam HA, Rossman GR: Oxalate nephrosis and crystalline myocarditis: case report with postmortem and crystallographic studies. Arch Pathol Lab Med 1974, 98:149–155.

    CAS  Google Scholar 

  31. West RR, Salyer WR, Hutchins GM: Adult onset primary oxalosis with complete heart block. Johns Hopkins Med 1973, 133:195–200.

    CAS  Google Scholar 

  32. Furby A, Mourtada R, Charasse C, et al.: Polyradiculopathy in an adult with primitive hyperoxaluria. Rev Neurol 2000, 156:62–64.

    PubMed  CAS  Google Scholar 

  33. Moorhead PJ, Cooper DJ, Timperley WR: Progressive peripheral neuropathy in a patient with primary hyperoxaluria. Br Med J 1975, 2:312–313.

    PubMed  CAS  Google Scholar 

  34. Alcorn DM, Fredrick DR: Ophthalmic features of primary oxalosis after combined liver/kidney transplantation. Br J Ophthalmol 2000, 84:1326–1327.

    Article  PubMed  CAS  Google Scholar 

  35. Farreli J, Shoemaker JD, Otti T, et al.: Primary hyperoxaluria in an adult with renal failure, livedo reticularis, retinopathy, and peripheral neuropathy. Am J Kidney Dis 1997, 29:947–952.

    PubMed  CAS  Google Scholar 

  36. Lasram L, Kammoun A, Karray T, et al.: Ocular signs of primary hyperoxaluria type I. J Fr Ophthalmol 1997, 20:258–262.

    CAS  Google Scholar 

  37. Hricik DE, Hussain R: Pancytopenia and hepatosplenomegaly in oxalosis. Arch Intern Med 1984, 144:167–168.

    Article  PubMed  CAS  Google Scholar 

  38. Walter MJ, Dang CV: Pancytopenia secondary to oxalosis in a 23-year old woman. Blood 1998, 91:4394.

    PubMed  CAS  Google Scholar 

  39. Frishberg Y, Feinstein S, Rinat C, Drukker A: Hypothyroidism in primary hyperoxaluria type 1. J Pediatr 2000, 136:255–257.

    Article  PubMed  CAS  Google Scholar 

  40. Somach SC, Davis BR, Paras FA, et al.: Fatal cutaneous necrosis mimicking calciphylaxis in a patient with type 1 primary hyperoxaluria. Arch Dermatol 1995, 131:821–823.

    Article  PubMed  CAS  Google Scholar 

  41. Boor A, Jurkovic I, Friedmann I, et al.: Calcium oxalate granuloma of the nose of a chronically dialyzed nephritic patient. J Laryngol Otol 2001, 11:514–516.

    Google Scholar 

  42. Kazama-Saegusa S, Kazama JJ, Sugaya H, et al.: A case of late onset primary hyperoxaluria type 1 (PH1) presented with a black liver. Clin Nephrol 1998, 50:184–187. A 63-year-old woman with primary hyperoxaluria type 1 (PH1), who had received hemodialysis therapy for the last 4 years since she was diagnosed with chronic renal failure, had multiple joint pain and mild liver dysfunction. Laparoscopy revealed a black liver. Histologic studies showed numerous lipofuscin-like dark brown granules deposited inside the hepatocytes. Therefore, black liver may be related to a mild form of PH1.

    PubMed  CAS  Google Scholar 

  43. Kamoun A, Daudon M, Zghal A, et al.: Primary hyperoxaluria: Tunisian experience apropos of 24 pediatric cases. Nephrologie 1997, 18:59–64.

    PubMed  CAS  Google Scholar 

  44. Ogawa Y, Hatano T: Primary hyperoxaluria type 1 (PH1). Ryoikibetsu Shokogun Shirizu 1998, 19:335–339.

    PubMed  Google Scholar 

  45. Ichiyama A, Oda T, Maeda-Nakai E: Primary hyperoxaluria type 1 in Japan. Cell Biochem Biophys 2000, 32:171–176. This study suggests that for herbivores, the peroxisomal localization of serine:pyruvate/alanine:glyoxylate aminotransferase (SPT/AGT) is indispensable to avoid massive production of oxalate. After examining eight cases of hyperoxaluria in Japan, the symptoms of some of the elderly Japanese patients with PH1 are milder than those of Western patients, probably as a result of a different diet. The reason is unclear, but an association of grass-eating with peroxisomal localization of SPT/AGT may be related in part to the food habits of the Japanese, especially that of the older generation. They prefer boiled greens rather than fried or raw vegetables.

    Article  PubMed  CAS  Google Scholar 

  46. Rinat C, Wanders RJ, Drukker A, et al.: Primary hyperoxaluria type 1: a model for multiple mutations monogenic disease within a distinct ethnic group. J Am Soc Nephrol 1999, 10:2352–2358. Seven mutations were detected in eight families in Israel. All but one of the mutations were in a homozygous pattern, reflecting a high rate of consanguinity in the patient population. Two affected brothers were homozygous for two different mutations expressed on the same allele. The population comprise a distinct ethnic group (Israeli/Arab).

    PubMed  CAS  Google Scholar 

  47. Canavese C, Salomone M, Massara C, et al.: Primary oxalosis mimicking hyperparathyroidism diagnosed after long-term hemodialysis. Am J Nephrol 1990, 10:344–349.

    Article  PubMed  CAS  Google Scholar 

  48. Julian BA, Faugere MC, Malluche HH: Oxalosis in bone causing a radiographical mimicry of renal osteodystrophy. Am J Kidney Dis 1987, 9:436–440.

    PubMed  CAS  Google Scholar 

  49. Toussaint C, DePauw L, Tielemans C, Abramowicz D: Hypercalcemia complicating systemic oxalosis in primary hyperoxaluria type 1. Nephrol Dial Transplant 1995, 10:17–21.

    PubMed  Google Scholar 

  50. Hoppe B, Danpure CJ, Rumsby G, et al.: A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymatic, phenotype, and disease severity. Am J Kidney Dis 1997, 29:36–44.

    PubMed  CAS  Google Scholar 

  51. Amoroso A, Pirulli D, Puzzer D, et al.: Gene symbols: AGXT. Disease: primary hyperoxaluria type 1. Hum Genet 1999, 104:441.

    Article  PubMed  CAS  Google Scholar 

  52. Nogueira PK, Vuong TS, Bouton O, et al.: Partial deletion of the AGXT gene (EX1_EX7 del): a new genotype in hyperoxaluria type 1. Hum Mutat 2000, 15:384–385.

    Article  PubMed  CAS  Google Scholar 

  53. Basmaison O, Rolland MO, Cochat P, Bozon D: Identification of 5 novel mutations in the AGXT gene. Hum Mutat 2000, 15:577.

    Article  PubMed  CAS  Google Scholar 

  54. Lumb MJ, Danpure CJ: Functional synergism between the most common polymorphism in human alanine: glyoxylate aminotransferase and four of the most common diseasecausing mutations. J Biol Chem 2000, 275:36415–36422.

    Article  PubMed  CAS  Google Scholar 

  55. Petrarulo M, Vitale C, Facchini P, Marangella M: Biochemical approach to diagnosis and differentiation of primary hyperoxalurias: an update. J Nephrol 1998, 11:23–28.

    Article  PubMed  Google Scholar 

  56. Chlebeck PT, Milliner Smith LH: Long term prognosis in primary hyperoxaluria type 2 (1-glyceric aciduria). Am J Kidney Dis 1994, 23:255–259.

    PubMed  CAS  Google Scholar 

  57. Kemper MJ, Conrad S, Muller-Wiefel DE: Primary hyperoxaluria type 2. Eur J Pediatr 1997, 156:509–512. Because of hyperoxaluria, primary hyperoxaluria should be considered in any patient with urolithiasis or nephrocalcinosis. The metabolic defect is a deficiency of D-glycerate dehydrogenase/glyoxylate reductase leading to hyperoxaluria and excretion of L-glycerate, which is the cornerstone of the diagnosis of primary hyperoxaluria type 2. This is a review of 24 patients reported in the literature, stressing the risk of urolithiasis, nephrocalcinosis, and terminal renal failure because renal prognosis may be worse than previously anticipated. Recent reports indicate that chronic and terminal renal insufficiency may occur. Therefore, long-term follow-up is necessary.

    Article  PubMed  CAS  Google Scholar 

  58. Webster KE, Ferree PM, Holmes RP, Cramer SD: Identification of missense, nonsense, and deletion mutations in the GRHPR gene in the patients with primary hyperoxaluria type II (PH2). Hum Genet 2000, 107:176–185.

    Article  PubMed  CAS  Google Scholar 

  59. Cregeen DP, Rumsby G: Recent developments in our understanding of primary hyperoxaluria type 2. J Am Soc Nephrol 1999, 10:348–350.

    Google Scholar 

  60. Webster KE, Cramer SD: Genetic basis of primary hyperoxaluria type 2. Mol Urol 2000, 4:355–364.

    PubMed  CAS  Google Scholar 

  61. Buno Soto A, Torres Jimenez R, Olveira A, et al.: Lithogenic risk factors for renal stones in patients with Crohn’s. Arch Exp Urol 2001, 54:282–292.

    CAS  Google Scholar 

  62. Chadwick VS, Modha K, Dowling RH: Mechanism for hyperoxaluria in patients with ileal dysfunction. N Engl J Med 1973, 289:172–176.

    Article  PubMed  CAS  Google Scholar 

  63. Allen A, Clutterbuck E, Maidment G, et al.: Enteric hyperoxaluria and renal failure associated with lymphangiectasia. Nephrol Dial Transplant 1997, 12:802–806.

    Article  PubMed  CAS  Google Scholar 

  64. Louthrenco W, Park YS, Philippe L, Schumacher HR: Localized peripheral calcium oxalate crystal deposition caused by Aspergillus niger infection. J Rheumatol 1990, 17:407–412.

    Google Scholar 

  65. Pecorella I, McCartney AC, Lucas S, et al.: Histological study of oxalosis in the eye and adnexa of AIDS patients. Histopathology 1995, 275:431–438.

    Article  Google Scholar 

  66. Benhamou CL, Bardin T, Tourliere D, et al.: [Bone involvement in primary oxalosis: study of 20 cases]. Rev Rhum Mal Osteoartic 1991, 58:763–769.

    PubMed  CAS  Google Scholar 

  67. Scnitzler CM, Kok JA, Jacobs DW, et al.: Skeletal manifestations of primary oxalosis. Pediatr Nephrol 1991, 5:193–199.

    Article  Google Scholar 

  68. Desmond P, Hennessy O: Skeletal abnormalities in primary oxalosis. Aust Radiol 1993, 37:83–85.

    CAS  Google Scholar 

  69. Knight RQ, Taddonio RF, Smith FB, et al.: Oxalosis: cause of degenerative spinal stenosis: a case report and review of the literature. Orthopedics 1998, 11:955–958.

    Google Scholar 

  70. Javier RM, Moulin B, Durckel J, et al.: Unusual heel pain in a patient with primary oxalosis treated by liver-kidney transplantation. Rev Rheum 1998, 65:517–518.

    CAS  Google Scholar 

  71. Kuo LW, Horton K, Fishman EK: CT evaluation of multisystem involvement by oxalosis. AJR Am J Roentgenol 2001, 177:661–663.

    PubMed  CAS  Google Scholar 

  72. Bahram S, Lutz LL: Cutaneous oxalate granuloma. J Am Acad Dermatol 1990, 22:316–317.

    Google Scholar 

  73. Isonokamu M, Nishida K, Okada N: Cutaneous oxalate granulomas in a hemodialysed patient: report of a case with unique clinical features. Br J Dermatol 1993, 128:690–692.

    Article  Google Scholar 

  74. Frieberg AA, Fish DN, Louis DS: Hand manifestations of oxalosis. J Hand Surg Am 1993, 18:140–142.

    Google Scholar 

  75. Schumachar HR, Reginato AJ, Pullman S: Synovial fluid oxalate deposition complicating rheumatoid arthritis with amyloidosis and renal failure: demonstration of intracellular oxalate crystals. J Rheumatol 1987, 4:361–366.

    Google Scholar 

  76. Holmes RP: Pharmacological approaches in the treatment of primary hyperoxaluria. J Nephrol 1998, 11:32–35.

    PubMed  Google Scholar 

  77. Sidhu H, Allison MJ, Clark A, Peck AB: Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol 2001, 166:1487–1491. This study showed that probiotic treatment of hyperoxaluric rats with gut-inhabiting bacterium Oxalobacter formigenes may significantly and rapidly reduce the level of oxalate in the urine by maintaining oxalic acid homeostasis through degradation of dietary oxalate. Therefore, O. formigenes could be used for the treatment of calcium oxalate kidney stone disease.

    Article  PubMed  CAS  Google Scholar 

  78. Jamieson NV: The results of combined liver/kidney transplantation for primary hyperoxaluria during 1984–1997. The European PH1 transplant registry report. European PH1 Transplantation Study Group. J Nephrol 1998, 11:36–41. This was a multicenter European study performed on 80 patients between 1984 and 1987, which showed that after transplantation, 1-, 2-, and 5-year survival rates were 88%, 80%, and 72%, respectively. Therefore, combined liver/kidney transplantation appears to have excellent results in patients with primary hyperoxaluria type 1, but patients with advanced systemic oxalosis have poor results after transplantation.

    PubMed  Google Scholar 

  79. Watts RW, Morgan SH, Danpure CJ, et al.: Combined hepatic and renal transplantation in primary hyperoxaluria type 1: report of nine cases. Am J Med 1991, 90:179–188.

    PubMed  CAS  Google Scholar 

  80. Watts RW, Danpure CJ, De Pauw L, Toussaint C: Combined liver/kidney and isolated liver transplantations for primary hyperoxaluria type 1: the European experience. The European Study Group on Transplantation for Hyperoxaluria Type 1. Nephrol Dial Transplant 1991, 6:502–511.

    PubMed  CAS  Google Scholar 

  81. Jamieson NV: The European Primary Hyperoxaluria Type 1 Transplant Registry report on the results of combined liver/ kidney transplantation for primary hyperoxaluria 1984– 1994. European PH1 Transplantation Study Group. Nephrol Dial Transplant 1995, 10:33–37.

    PubMed  Google Scholar 

  82. Bilgin N, Tirnaksiz MB, Moray G, et al.: Early recurrence of oxalate deposition after renal transplantation in a patient with primary hyperoxaluria type 1. Transplant Proc 1999, 31:3219–3220.

    Article  PubMed  CAS  Google Scholar 

  83. Saborio P, Scheinman JI: Transplantation for primary hyperoxaluria in the United States. Kidney Int 1999, 56:1094–1100. This study was performed on 280 patients with transplantation for primary hyperoxaluria. The article suggests that kidney transplantation offers better patient survival rates in the United States than kidney/liver transplantation or no transplantation.

    Article  PubMed  CAS  Google Scholar 

  84. Shapiro R, Weismann I, Mandel H, et al.: Primary hyperoxaluria type 1: improved outcome with timely liver transplantation: a single center-report of 36 children. Transplantation 2001, 72:428–432. This study on 36 children supports the strategies for early diagnosis and timely liver transplantation. Transplantation should be considered in children who develop the disease during infancy and in children with slowly progressive disease with significant symptoms. Combined liver/kidney transplantation is suggested for children with end-stage renal disease.

    Article  PubMed  CAS  Google Scholar 

  85. Kemper MJ, Nolkemper D, Rogiers X, et al.: Preemptive liver transplantation in primary hyperoxaluria type 1: timing and results. J Nephrol 1998, 11:46–48.

    PubMed  Google Scholar 

  86. Toussaint C, Vienne A, De Pauw L, et al.: Combined liverkidney transplantation in primary hyperoxaluria type 1: bony histopathology and oxalate body content. Transplantation 1995, 59:1700–1704.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cooper Hospital/University Medical Center, Education and Research Building, Suite 262, 401 North Haddon Avenue, 08103, Camden, NJ, USA

    Antonio J. Reginato MD

Authors
  1. Irama Maldonado MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vineet Prasad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio J. Reginato MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maldonado, I., Prasad, V. & Reginato, A.J. Oxalate crystal deposition disease. Curr Rheumatol Rep 4, 257–264 (2002). https://doi.org/10.1007/s11926-002-0074-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-002-0074-1

Keywords

Search

Navigation